This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.

Inclusion Criteria:

• Ability and willingness to provide written informed consent.
• Sufficiently fluent in English to participate in the trial.
• Male and female patients aged 18-70 years (inclusive).

Exclusion Criteria:

• Lifetime history of bipolar disorder, schizophrenia, psychosis, seizures, delusional disorders or obsessive-compulsive disorder.
• Current or planned pregnancy or nursing during the trial period.
• A positive test for substances of abuse.